Abstract Library

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#3305 177Lu-Dotatate efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase 2 prospective clinical trials

Introduction: Neuroendocrine tumors are a rare neoplasia. At least 25% of patients (pts) with advanced disease may have functioning neuroendocrine tumors (F-NETs) that can secrete bioactive peptides that can lead to specific symptoms like diarrhea that can be debilitating and life-threatening.Although symptom relief is available with somatostatin analogs (SSA), the disease eventually becomes refractory to SSA,leaving no proven treatment options

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M,

Keywords: neuroendocrine tumor, carcinoid syndrome, neuroendocrine neoplasia, PRRT, insulinoma, 177Lu-Dotatate, functioning tumor,

#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs

Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Kidd M, Bodei L, Severi S, Drozdov I, Nicolini S,

Keywords: PRRT, nomogram, NETest, biomarker, OS, PFS, prediction,

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,

Keywords: NETest, PRRT,

#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sansovini M

Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,

Keywords: PRRT, FDG-PET, P-NET,